Largest biotech companies by total debt
Borrowings at the end of the latest fiscal year: long-term debt including the part due within a year, plus short-term borrowings. Leases are left out unless the company reports them in one figure with its debt.
Amgen leads the 11 biotech companies ranked by total debt, at CHF 46.1B, ahead of Gilead Sciences (CHF 21B) and Biogen (CHF 5.3B). Figures as of 18 Nov 2026, 19:11 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 11
- First
- AmgenCHF 46.1B
- Median
- CHF 497.7M
- Combined market value
- CHF 705.8B
- Countries
- 5
- Not ranked
- 13no total debt on file
Market values as of .
All countries▾
All sectors▾
Biotech▾
| # | Company | Total debt ↓ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | AmgenAMGN · Health Care | CHF 46.1B | CHF 202.3B | CHF 373.99 | 3.18% down | 34% up | ||
| 2 | Gilead SciencesGILD · Health Care | CHF 21B | CHF 176.6B | CHF 142.36 | 0.88% down | 33% up | ||
| 3 | BiogenBIIB · Health Care | CHF 5.3B | CHF 31.2B | CHF 211.31 | 0.12% down | 49% up | ||
| 4 | Halozyme TherapeuticsHALO · Health Care | CHF 1.8B | CHF 9.2B | CHF 81.05 | 0.12% up | 37% up | ||
| 5 | QiagenQGEN · Health Care | CHF 1.4B | CHF 8.7B | CHF 41.92 | 0.12% down | 12% up | ||
| 6 | ModernaMRNA · Health Care | CHF 497.7M | CHF 67.9B | CHF 167.76 | 3.83% down | 755% up | ||
| 7 | RepligenRGEN · Health Care | CHF 457.4M | CHF 9.2B | CHF 144.66 | 5.74% up | 5% up | ||
| 8 | Bio-TechneTECH · Health Care | CHF 168.7M | CHF 9.6B | CHF 61.40 | 0.21% up | 26% up | ||
| 9 | Adaptive BiotechnologiesADPT · Health Care | CHF 110.7M | CHF 3.9B | CHF 24.13 | 0.39% up | 88% up | ||
| 10 | Scholar Rock HoldingSRRK · Health Care | CHF 84.1M | CHF 4.9B | CHF 40.02 | 5.25% up | 14% up | ||
| 11 | CG OncologyCGON · Health Care | CHF 2.5M | CHF 6B | CHF 66.85 | 0.39% up | 85% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration; annual figures from the reports companies file with the SEC.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Total debt is from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day, not of the period. Total debt is assembled from each company's debt lines and is the least complete of these figures: some companies tag part of their borrowings in ways it misses. Sums are converted from US dollars at today's exchange rate (1 USD = 0.8436 CHF). 13 companies have no total debt on file and are not ranked here.
Questions and answers
Which biotech companies rank first by total debt?
Amgen (CHF 46.1B), Gilead Sciences (CHF 21B) and Biogen (CHF 5.3B) are the top three of the 11 biotech companies ranked by total debt as of 18 Nov 2026, 19:11 UTC.
How many biotech companies are in this ranking?
11 are ranked by total debt. 13 more have no total debt on file and are left out rather than ranked at zero.
What are these biotech companies worth together?
The 11 biotech companies ranked by total debt have a combined market value of CHF 705.8B as of 18 Nov 2026, 19:11 UTC.
What does ranking by total debt measure?
Borrowings at the end of the latest fiscal year: long-term debt including the part due within a year, plus short-term borrowings. Leases are left out unless the company reports them in one figure with its debt.
Learn how this ranking works
All markets guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Largest biotech companies by total debt”, data as of 18 November 2026. https://funkfolio.com/companies/category/biotech?by=total-debt
Underlying data: Yahoo Finance; SEC EDGAR.